Life science company Acucort is now focusing on continued international expansion after the launch in the Nordic region and a new commercial agreement with Glenmark Pharmaceuticals in Europe. The next major goal is the US market, where the company plans to submit an application for market approval to the FDA before the end of the year. This is stated by CEO Jonas Jönmark in a newsletter. Looking ahead, the focus is on continuing to strengthen the presence in existing markets, developing new partnerships and advancing the regulatory process in the US, the company says. – We have built a solid foundation and can now see how our work is starting to pay off. At the same time, we are still at the beginning of our international journey, Jonas Jönmark says.